ArticleMolecular psychiatry2026
Serotonergic SLC10A4 regulates extracellular serotonin levels and antidepressant responsiveness.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Solute carrier family member 10A4 (SLC10A4) is an orphan transporter selectively expressed in aminergic cells, where it localizes to synaptic vesicles and has been implicated in aminergic neurotransmission. Although constitutive knockout studies have suggested a role for SLC10A4 in monoamine and acetylcholine homeostasis, interpretation has been limited by developmental compensation and lack of cell-type specificity. Here, we employed a tamoxifen-inducible CreERT2-lox system to selectively delete Slc10a4 in serotonergic neurons of young adult mice (8-10 weeks), enabling assessment of its function in mature serotonergic circuits. Adult serotonergic deletion of SLC10A4 resulted in a marked reduction of baseline extracellular serotonin levels in the medial prefrontal cortex, as measured by in vivo microdialysis. Notably, the ability of the selective serotonin reuptake inhibitor fluoxetine to elevate extracellular serotonin was strongly attenuated. These neurochemical deficits were accompanied by increased anxiety-like behavior across multiple behavioral paradigms and a blunted antidepressant-like response to fluoxetine in the forced swim test, while locomotor activity and motor coordination remained intact. These findings show that SLC10A4 is required for normal extracellular serotonin availability and antidepressant responsiveness in the adult brain. Together, our results identify SLC10A4 as a novel critical regulator of serotonergic neurotransmission and suggest that presynaptic monoamine handling represents an important and previously underappreciated determinant of affective behavior and treatment efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.